Keith Reimann

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses
    Keith A Reimann
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 79:8878-85. 2005
  2. ncbi Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques
    Robert A Rasmussen
    Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    AIDS 16:829-38. 2002
  3. ncbi Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys
    Sallie R Permar
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Infect Dis 190:998-1005. 2004
  4. ncbi Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys
    Sallie R Permar
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 77:4396-400. 2003
  5. ncbi In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys
    Elisa I Choi
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 82:6758-61. 2008
  6. ncbi Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques
    Elisa I Choi
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Immunology 124:215-22. 2008
  7. ncbi A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus
    Keith A Reimann
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Research East 113, 330 Brookline Avenue, Boston, MA 02215, USA
    AIDS Res Hum Retroviruses 18:747-55. 2002
  8. ncbi Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques
    Jörn E Schmitz
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, RE 113, 330 Brookline Ave, Boston, Massacusetts 02215, USA
    J Virol 79:8131-41. 2005
  9. ncbi Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates
    Louis Boon
    Tanox Pharma B.V, Amsterdam, The Netherlands
    Toxicology 172:191-203. 2002
  10. ncbi CD8+ cell depletion amplifies the acute retroviral syndrome
    Lisa J Madden
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Neurovirol 10:58-66. 2004

Research Grants

  1. IMMUNOLOGIC MECHANISMS CONTROLLING SIV REPLICATION
    Keith Reimann; Fiscal Year: 2002
  2. RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES
    Keith Reimann; Fiscal Year: 2004
  3. RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES
    Keith Reimann; Fiscal Year: 2009
  4. RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES
    Keith Reimann; Fiscal Year: 2009
  5. RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES
    Keith A Reimann; Fiscal Year: 2010
  6. CHIMERIC SHIV MODEL FOR EVALUATING HIV IMMUNOTHERAPIES
    Keith Reimann; Fiscal Year: 2001
  7. RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES
    Keith A Reimann; Fiscal Year: 2010

Collaborators

Detail Information

Publications16

  1. ncbi Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses
    Keith A Reimann
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 79:8878-85. 2005
    ....
  2. ncbi Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques
    Robert A Rasmussen
    Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    AIDS 16:829-38. 2002
    ..In addition, the results suggest that in the absence of CD8+ T cells, nAb may act as an effective second line of defense by limiting both the spread of infectious virus to new target cells and CD4+ T-cell loss...
  3. ncbi Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys
    Sallie R Permar
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Infect Dis 190:998-1005. 2004
    ....
  4. ncbi Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys
    Sallie R Permar
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 77:4396-400. 2003
    ..These findings indicate a central role for CD8(+) lymphocytes in the control of measles virus infections and the importance of eliciting a cell-mediated immune response in new measles vaccine strategies...
  5. ncbi In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys
    Elisa I Choi
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 82:6758-61. 2008
    ..These findings are consistent with a limited role for cytotoxic CD16(+) NK cells in the control of primary SIV viremia...
  6. ncbi Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques
    Elisa I Choi
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Immunology 124:215-22. 2008
    ..These studies describe a non-human primate model for in vivo NK-cell depletion and suggest a limited role for cytotoxic CD16(+) NK cells in controlling AIDS virus replication during chronic infection...
  7. ncbi A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus
    Keith A Reimann
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Research East 113, 330 Brookline Avenue, Boston, MA 02215, USA
    AIDS Res Hum Retroviruses 18:747-55. 2002
    ..These results support the overall concept of anti-CD4 monoclonal antibody treatment to suppress AIDS virus replication in vivo while demonstrating important issues as to its clinical feasibility...
  8. ncbi Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques
    Jörn E Schmitz
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, RE 113, 330 Brookline Ave, Boston, Massacusetts 02215, USA
    J Virol 79:8131-41. 2005
    ....
  9. ncbi Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates
    Louis Boon
    Tanox Pharma B.V, Amsterdam, The Netherlands
    Toxicology 172:191-203. 2002
    ..Together, the results from these preclinical studies support the studies of the anti-HIV-1 effect of hu5A8 in HIV-1 infected individuals...
  10. ncbi CD8+ cell depletion amplifies the acute retroviral syndrome
    Lisa J Madden
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Neurovirol 10:58-66. 2004
    ..CD8+ cell depletion, therefore, appears to enhance symptoms of the acute retroviral syndrome and alters several of the immunological factors associated with the early phase of infection...
  11. ncbi Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
    Daniel R Kuritzkes
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA
    J Infect Dis 189:286-91. 2004
    ..We wished to determine the safety and anti-human immunodeficiency virus (HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent activity against HIV-1 in vitro, in HIV-infected subjects...
  12. ncbi Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency
    Monica Vaccari
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bldg 41, Room D804, Bethesda, MD 20892, USA
    J Virol 82:9629-38. 2008
    ....
  13. ncbi Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus
    Yvette Edghill-Smith
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, 41/D804, Bethesda, Maryland 20892, USA
    Nat Med 11:740-7. 2005
    ..Thus, vaccines able to induce long-lasting protective antibody responses may constitute realistic alternatives to the currently available smallpox vaccine (Dryvax)...
  14. ncbi Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection
    Naglaa H Shoukry
    Center for Vaccines and Immunity, Columbus Children's Research Institute, Columbus, OH 43205, USA
    J Exp Med 197:1645-55. 2003
    ..These experiments demonstrate an essential role for memory CD8+ T cells in long-term protection from chronic hepatitis C...
  15. ncbi CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection
    Robert Thimme
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:68-76. 2003
    ....

Research Grants23

  1. IMMUNOLOGIC MECHANISMS CONTROLLING SIV REPLICATION
    Keith Reimann; Fiscal Year: 2002
    ....
  2. RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES
    Keith Reimann; Fiscal Year: 2004
    ....
  3. RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES
    Keith Reimann; Fiscal Year: 2009
    ....
  4. RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES
    Keith Reimann; Fiscal Year: 2009
    ....
  5. RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES
    Keith A Reimann; Fiscal Year: 2010
    ....
  6. CHIMERIC SHIV MODEL FOR EVALUATING HIV IMMUNOTHERAPIES
    Keith Reimann; Fiscal Year: 2001
    ..II. Utilize this model to evaluate a unique, humanized anti-CD4 antibody as an anti-viral therapy for the treatment and prevention of HIV infection. ..
  7. RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES
    Keith A Reimann; Fiscal Year: 2010
    ....